TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies. Its technology platforms comprise PEGylation Technology designed to enhance the performance of various drug classes, including macromolecules, small molecules, and other drugs. The company?s technologies are used in 10 approved products; 3 partner programs that have been filed for with the FDA; and 12 development programs in human clinical trials. Its partnered products include NKTR-061, a Phase II clinical product for gram-negative pneumonias; and Ciprofloxacin Inhalation Powder, a Phase II clinical product for lung infections. The company?s partnered product portfolio also comprises Neulasta for neutropenia; PEGASYS for Hepatitis-C; Somavert for Acromegaly; PEG-INTRON for Hepatitis-C; Macugen for age-related macular degeneration; CIMZIA for Crohn's disease; MIRCERA for renal anemia and chronic kidney disease; CIMZIA for rheumatoid arthritis; Hematide, a Phase III product for Anemia; MAP0004, a Phase III product for Migraine; Macugen, a Phase II clinical trial product for diabetic macular edema and retinal vein occlusion; and CDP 791, a Phase II product for nonsmall cell lung cancer. In addition, Nektar?s proprietary products include NKTR-105 (PEGylated docetaxel) for colorectal and non-small-cell lung cancer; NKTR-102, a Phase II trial product for colorectal cancer, metastatic breast, metastatic cervical cancer, and platinum resistant ovarian cancer; NKTR-118, a Phase II product for opioid-induced constipation and other manifestations of opioid bowel dysfunction; and NKTR-063 (inhaled vancomycin), a proprietary antibiotic being developed for Gram-positive pneumonia, including MRSA infections, which is in Phase I clinical trials in the U.K. and scheduled to enter Phase II trials in the U.S. in the first half of 2009. The company was founded in 1990 and is headquartered in San Carlos, California.

Last Trade Date
Change % Price Change
Open 52 Week High
High 52 Week Low
Low Type
Volume Average Volume
Prev Close Stock Exchange
Bid Ask
Bid Size Ask Size
1st Yr Estimated EPS Growth 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share Book Value Yield
Buy Back Yield CAPE Ratio
Cash Return Cash Flow per Share
Cash Flow Yield Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue EV / Pre Tax Income
EV / Revenue EV / Total Asset
Expected Dividend Growth Rate Free Cash Flow per Share
Free Caash Flow Ratio Free Cash Flow Yield
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio
PB Ratio PB Ratio 10 Year Growth
PB Ratio 3 Year Growth Cash Ratio 3 Year Average
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month
Price to Cash Ratio Price / EBITDA
Price to Sales Ratio Price to Sales Ratio 10 Year Growth
Price to Sales Ratio 3 Year Avg Price to Sales Ratio 5 Year Avg
Sale per Share Sales Yield
Sustainable Growth Rate Tangible Book Value per Share
Tangible Book Value per Share 3 year Avg Tangible Book Value per Share 5 year Avg
Total Asset per Share Total Yield
Working Capital per Share Working Capital per Share 3 Year Avg
Working Capital per Share 5 Year Avg Beta